ReviewJournal of clinical medicine2025
Augmented Decisions: AI-Enhanced Accuracy in Glaucoma Diagnosis and Treatment.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Risk-Stratified Interventional Management and Surgical Decision-Making in Primary Glaucoma.Biomedicines · 2026Review
- Explainable Multimodal OCT and OCTA Analysis Reveals Structural and Vascular Features of Mild Glaucoma Across Ethnicities.Investigative ophthalmology & visual science · 2026Observational
- A Review of the Use of Artificial Intelligence in Ophthalmology Imaging: Approximation to Ocular Histopathology.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Review
- Teleophthalmology and Teleglaucoma in Clinical Practice: Attitudes of Ophthalmologists in Bulgaria.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma remains a leading cause of irreversible blindness. We reviewed more than 150 peer-reviewed studies (January 2019-July 2025) that applied artificial or augmented intelligence (AI/AuI) to glaucoma care. Deep learning systems analyzing fundus photographs or OCT volumes routinely achieved area-under-the-curve values around 0.95 and matched-or exceeded-subspecialists in prospective tests. Sequence-aware models detected visual field worsening up to 1.7 years earlier than conventional linear trends, while a baseline multimodal network integrating OCT, visual field, and clinical data predicted the need for incisional surgery with AUROC 0.92. Offline smartphone triage in community clinics reached sensitivities near 94% and specificities between 86% and 94%, illustrating feasibility in low-resource settings. Large language models answered glaucoma case questions with specialist-level accuracy but still require human oversight. Key obstacles include algorithmic bias, workflow integration, and compliance with emerging regulations, such as the EU AI Act and FDA GMLP. With rigorous validation, bias auditing, and transparent change control, AI/AuI can augment-rather than replace-clinician expertise, enabling earlier intervention, tailored therapy, and more equitable access to glaucoma care worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.